210
Participants
Start Date
August 31, 2023
Primary Completion Date
September 19, 2024
Study Completion Date
September 19, 2024
ONO-2910
ONO-2910 Tablet will be orally administered once daily.
Placebo
Placebo Tablet will be orally administered once daily.
Fujita Health University Hospital, Aichi
Nagoya City University Hospital, Aichi
Nagoya University Hospital, Aichi
Funabashi Municipal Medical Center, Chiba
Medical Corporation Tesshokai Kameda Medical Center, Chiba
National Cancer Center Hospital East, Chiba
Kitakyushu City Hospital Organization Kitakyushu Municipal Medical Center, Fukuoka
Gunma Prefectural Cancer Center, Gunma
University of Tsukuba Hospital, Ibaraki
Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima
Nippon Medical School Musashikosugi Hospital, Kanagawa
Tokai University Hospital, Kanagawa
Kumamoto Shinto General Hospital, Kumamoto
Kumamoto University Hospital, Kumamoto
Okayama University Hospital, Okayama
Nahanishi Clinic, Okinawa
Osaka Breast Clinic, Osaka
Osaka Prefectural Hospital Organization Osaka International Cancer Institute, Osaka
Osaka Rosai Hospital, Osaka
Osaka University Hospital, Osaka
Yodogawa Christian Hospital, Osaka
Japanese Saitama Red Cross Hospital, Saitama
Saitama Medical University International Medical Center, Saitama
Shizuoka General Hospital, Shizuoka
Center Hospital of the National Center for Global Health and Medicine, Tokyo
National Cancer Center Hospital, Tokyo
Nippon Medical School Hospital, Tokyo
St. Luke's International Hospital, Tokyo
Tokyo Metropolitan Komagome Hospital, Tokyo
Toranomon Hospital, Tokyo
Lead Sponsor
Ono Pharmaceutical Co. Ltd
INDUSTRY